Lyell Immunopharma Inc

Chinook Therapeutics, Inc., now a Novartis Company, is a clinical-stage biopharmaceutical company based in Seattle, WA. They specialize in the discovery, development, and commercialization of precision medicines for rare and severe chronic kidney diseases, with a particular focus on IgA nephropathy. With a strong pipeline of innovative therapies, Chinook is dedicated to changing the course of kidney care and improving the lives of patients suffering from these debilitating conditions. As a leader in the field, Chinook Therapeutics is committed to advancing the understanding and treatment of chronic kidney diseases through rigorous scientific research and clinical trials. Their precision medicines, such as Atrasentan, Zigakibart BION-1301, and CHK-336, offer promising solutions for patients in need. With a patient-centric approach and a dedication to scientific excellence, Chinook Therapeutics is at the forefront of transforming kidney care and bringing hope to those affected by these challenging conditions.Generated from the website

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the development of innovative cancer treatments. Through science and technology, the company strives to develop and commercialize products that address unmet medical needs, improve survival and have a favorable safety profile. Additionally, Dendreon develops therapeutic vaccines that stimulate the body's immune system to help fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. The company also develops vaccines to treat breast, colorectal, lung, ovarian and uterine cancers along with monoclonal antibodies to fight blood cancers, such as non-Hodgkin's and B-cell lymphomas. Its partners include Japan's Kirin Brewery and Genentech. Dendreon Corporation is located in Seattle.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company based in Seattle, WA, dedicated to developing innovative bispecific immunotherapies for cancer treatment, with a focus on improving outcomes and transforming the lives of cancer patients. With a broad pipeline designed to target multiple mechanisms of action, Aptevo is at the forefront of advancing the science of immuno-oncology. Their lead candidate, APVO436, is specifically developed to combat Acute Myeloid Leukemia, demonstrating their commitment to developing meaningful therapeutics in the fight against cancer.Generated from the website